Universal Ibogaine Inc. (IBO.V)
CAD 0.03
(0.0%)
CAD 0.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -4.6 Million CAD | -22.43% |
| 2021 | -3.76 Million CAD | -589944.51% |
| 2020 | 638.00 CAD | 101.88% |
| 2019 | -33.86 Thousand CAD | -152.95% |
| 2018 | 63.95 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -346.66 Thousand CAD | 52.93% |
| 2023 Q2 | -736.54 Thousand CAD | -1.04% |
| 2023 Q1 | -728.96 Thousand CAD | 34.93% |
| 2022 Q1 | -1.48 Million CAD | -7964.19% |
| 2022 FY | - CAD | -22.43% |
| 2022 Q4 | -1.12 Million CAD | -4.37% |
| 2022 Q3 | -1.07 Million CAD | -16.03% |
| 2022 Q2 | -925.11 Thousand CAD | 37.85% |
| 2021 Q4 | -18.45 Thousand CAD | -130.58% |
| 2021 Q2 | 5566.00 CAD | -82.19% |
| 2021 Q3 | 60.36 Thousand CAD | 984.58% |
| 2021 FY | - CAD | -589944.51% |
| 2021 Q1 | 31.26 Thousand CAD | -19.76% |
| 2020 FY | - CAD | 101.88% |
| 2020 Q4 | 38.95 Thousand CAD | 164.8% |
| 2020 Q3 | 14.71 Thousand CAD | 434.9% |
| 2020 Q2 | -4393.00 CAD | -188.09% |
| 2020 Q1 | 4987.00 CAD | 133.42% |
| 2019 Q1 | -9329.00 CAD | 59.14% |
| 2019 FY | - CAD | -152.95% |
| 2019 Q4 | -14.92 Thousand CAD | -14.61% |
| 2019 Q3 | -13.02 Thousand CAD | -215.0% |
| 2019 Q2 | 11.32 Thousand CAD | 221.37% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | -22.83 Thousand CAD | 44.87% |
| 2018 Q3 | -41.41 Thousand CAD | -164.02% |
| 2018 Q1 | -178.95 Thousand CAD | -85.51% |
| 2018 Q2 | 64.69 Thousand CAD | 136.15% |
| 2017 Q4 | -96.47 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arch Biopartners Inc. | -430.71 Thousand CAD | -969.698% |
| Covalon Technologies Ltd. | -3.49 Million CAD | -31.955% |
| Hemostemix Inc. | -1.94 Million CAD | -136.79% |
| Kane Biotech Inc. | -3.23 Million CAD | -42.449% |
| MedMira Inc. | -1.57 Million CAD | -192.117% |
| Marvel Biosciences Corp. | -2.25 Million CAD | -104.59% |
| NervGen Pharma Corp. | -17.72 Million CAD | 74.001% |
| XORTX Therapeutics Inc. | -6.46 Million CAD | 28.773% |